CN111888396A - Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof - Google Patents
Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof Download PDFInfo
- Publication number
- CN111888396A CN111888396A CN202010782676.6A CN202010782676A CN111888396A CN 111888396 A CN111888396 A CN 111888396A CN 202010782676 A CN202010782676 A CN 202010782676A CN 111888396 A CN111888396 A CN 111888396A
- Authority
- CN
- China
- Prior art keywords
- parts
- cervical spondylosis
- root
- pharmaceutical composition
- active ingredients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a pharmaceutical composition for treating cervical spondylosis and a preparation method and application thereof, belonging to the technical field of medicines. The active ingredients of the pharmaceutical composition comprise the following two parts: (1) the active ingredients of the traditional Chinese medicine are as follows: 1-15 parts of pseudo-ginseng; 3-20 parts of ligusticum wallichii; 2-15 parts of corydalis tuber; 3-20 parts of white peony root; 4-25 parts of clematis root; 3-20 parts of kudzu roots; 4-25 parts of notopterygium root; (2) active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 1-4. The invention is a Chinese and western medicine combined medicine developed on the basis of Chinese patent CN1228071C, has unique curative effect on treating cervical spondylosis, and has the advantages of simple preparation process, obvious curative effect, short acting time, convenient administration, no toxic or side effect, safety and effectiveness.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating cervical spondylosis and a preparation method and application thereof.
Background
The information in this background section is only for enhancement of understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art that is already known to a person of ordinary skill in the art.
Cervical spondylotic radiculopathy is a common and frequently encountered disease in orthopedics and traumatology, is also the most common type of cervical spondylosis, and accounts for about 60-70% of the incidence rate. The concept related to cervical spondylosis in the earliest modern medicine is mostly derived from cervical spondylotic radiculopathy, which not only has high morbidity, but also is frequently recurrent and difficult to cure, seriously affects physical and mental health of patients, brings inconvenience to work, study and daily life of the patients, and causes other series of diseases for some patients.
Cervical spondylotic radiculopathy (blood stasis, qi stagnation and venation block) is caused by mechanical compression and chemical stimulation of nerve roots to produce congestion, edema and inflammatory reaction on the basis of intervertebral foramina stenosis, and is the category of arthralgia syndrome in traditional Chinese medicine. The etiology can be: 1. injuries caused by external force, including acute injuries and chronic strains; 2. the six exogenous pathogenic factors averse qi, wind cold dampness and evil damage, which leads to the failure of qi to circulate, failure of blood to circulate, qi and blood obstruction, failure of the tendon and vessel to warm, qi stagnation and blood stasis; 3. deficiency of the liver and kidney, congenital deficiency, the kidney governing bones, the liver governing tendons, and deficiency of the liver and kidney, the development of bones will generate deformation and abnormality of internal structure, and slight fatigue and injury will cause stagnation of qi and blood and pain. Clinically, the pain, stiffness or scurrying and scurrying of the neck, the shoulder and the upper limb are manifested as pain, fixed pain, tenderness of the pain, great pain for patients, and urgent treatment to relieve the pain as soon as possible.
The applicant filed and granted 'a medicament for treating cervical spondylosis and a preparation method thereof' (CN1228071C) in the previous period, and discloses a medicament for treating cervical spondylosis, which comprises the following components in parts by weight: 1-15 parts of pseudo-ginseng; 3-20 parts of ligusticum wallichii; 2-15 parts of corydalis tuber; 3-20 parts of white peony root; 4-25 parts of clematis root; 3-20 parts of kudzu roots; 4-25 parts of notopterygium root, for treating cervical spondylosis due to blood stasis, qi stagnation and obstruction of vessels. Products based on the patent technology are already on the market and named as 'neck pain granules' and other series products. Through clinical verification for many years, the traditional Chinese medicine composition has good curative effect on various cervical spondylosis such as nerve root type cervical spondylosis, vertebral artery type cervical spondylosis, spinal cord type cervical spondylosis, sympathetic type cervical spondylosis and mixed type cervical spondylosis, and particularly has outstanding curative effect on the nerve root type cervical spondylosis, so the traditional Chinese medicine composition is popular to patients. However, the traditional Chinese medicine compound has the problems of slow effect, long treatment course and the like in the treatment of cervical spondylosis, and western medicines have strong dependence and are often accompanied by strong toxic and side effects, so that the research of a traditional Chinese medicine and western medicine combined medicine for treating cervical spondylosis becomes one of important subjects of people research.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a pharmaceutical composition for treating cervical spondylosis and a preparation method and application thereof. The invention is a Chinese and western medicine combined medicine developed on the basis of Chinese patent CN1228071C, has unique curative effect on treating cervical spondylosis, and has the advantages of simple preparation process, obvious curative effect, short acting time, convenient administration, no toxic or side effect, safety and effectiveness.
In order to achieve the purpose, the invention relates to the following technical scheme:
in a first aspect of the present invention, there is provided a pharmaceutical composition for treating cervical spondylosis, wherein the active ingredients of the pharmaceutical composition comprise the following two parts:
(1) the active ingredients of the traditional Chinese medicine are as follows: in parts by weight, is prepared from
1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber
3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae
4-25 parts of notopterygium root.
(2) Active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 1-4.
In a second aspect of the present invention, there is provided a method for preparing the above pharmaceutical composition for treating cervical spondylosis, the method comprising preparing active ingredients of traditional Chinese medicines, specifically:
(1) pulverizing Notoginseng radix into 100-120 mesh fine powder;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, collecting the distilled water solution in another container, decocting the residue with water for 1 hr, and filtering to obtain filtrate;
(3) decocting radix Puerariae and radix Paeoniae alba with water twice (2 hr for the first time and 1 hr for the second time), mixing the filtrate with the above two water solutions, concentrating, precipitating with ethanol, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(4) reflux-extracting rhizoma Ligustici Chuanxiong and rhizoma corydalis with ethanol, removing residue, recovering ethanol from the extractive solution, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(5) mixing the above two fluid extracts, adding Notoginseng radix powder, mixing, drying, pulverizing into fine powder, adding appropriate amount of rhizoma Peucedani, mixing, and spraying the volatile oil of Notopterygii rhizoma and radix Clematidis.
In a third aspect of the present invention, an application of the above pharmaceutical composition for treating cervical spondylosis in preparing a pharmaceutical preparation for treating cervical spondylosis is provided.
In a fourth aspect of the invention, a pharmaceutical preparation for treating cervical spondylosis is provided, which is prepared from the pharmaceutical composition and pharmaceutically acceptable auxiliary materials.
The medicinal preparation can be prepared into various medicinal dosage forms, such as decoction, pills, capsules, tablets, powder, granules or oral liquid.
The beneficial technical effects of one or more technical schemes are as follows:
the technical scheme is a Chinese and western medicine combined medicine developed on the basis of Chinese patent CN1228071C, which overcomes the defect of slow effect of the traditional Chinese medicine composition, overcomes the toxic and side effects of western medicine components, is convenient to take, safe and effective, and has good values of practical application and popularization.
Detailed Description
It is to be understood that the following detailed description is exemplary and is intended to provide further explanation of the invention as claimed. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of exemplary embodiments according to the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise. It is to be understood that the scope of the invention is not to be limited to the specific embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
As mentioned above, the traditional Chinese medicine compound has the problems of slow effect, long treatment course and the like in the treatment of cervical spondylosis, and the western medicine has strong dependence and is often accompanied by strong toxic and side effects, so that the research of the traditional Chinese medicine and western medicine combined medicine for treating cervical spondylosis becomes one of the important subjects of people research.
In view of the above, in one embodiment of the present invention, a pharmaceutical composition for treating cervical spondylosis is provided, wherein the active ingredients of the pharmaceutical composition comprise the following two parts:
(1) the active ingredients of the traditional Chinese medicine are as follows: in parts by weight, is prepared from
1-15 parts of pseudo-ginseng, 3-20 parts of ligusticum wallichii, 2-15 parts of corydalis tuber
3-20 parts of radix paeoniae alba, 4-25 parts of radix clematidis, 3-20 parts of radix puerariae
4-25 parts of notopterygium root.
Wherein Notoginseng radix, rhizoma Ligustici Chuanxiong, and rhizoma corydalis have effects of promoting blood circulation, activating qi-flowing, removing blood stasis, and dredging collaterals; notopterygii rhizoma, radix Clematidis and radix Puerariae have effects of dispelling pathogenic wind, cold and dampness, and relieving neck rigidity; white peony root, radix Paeoniae alba, with its main effects of nourishing blood, softening yin, nourishing tendons and vessels, promoting blood circulation, removing blood stasis, promoting the circulation of qi and relieving pain.
(2) Active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 1-4.
The levetiracetam is chemically named as (S) -alpha-ethyl-2-oxo-1-pyrrolidine acetamide, is a selective 5-hydroxytryptamine reabsorption inhibitor, is mainly used as an antiepileptic drug at present, and is used for the additional treatment of partial seizures of adult and children over 4 years old epileptics.
Diclofenac sodium is chemically named as 2- (2, 6-dichlorophenyl) aminophenylsodium acetate, is currently used as an anti-inflammatory analgesic, and mainly achieves the anti-inflammatory analgesic effect by inhibiting cyclooxygenase to reduce synthesis of prostaglandin. It can be used for acute joint inflammation and gout attack, chronic joint inflammation, rheumatoid arthritis, other inflammatory rheumatic diseases of ankylosing spine joint and spine, pain related to degenerative diseases of joint and spine, soft tissue rheumatism, swelling pain or inflammation after trauma or surgery, treating dysmenorrhea and postoperative pain and inflammation caused by plastic, dental surgery or other minor surgical operations.
A large amount of experimental researches discover that when diclofenac sodium and the traditional Chinese medicine active ingredient of the application are jointly used, the effect is faster, the treatment effect is also improved, but the cardiovascular toxicity effect can be increased when the diclofenac sodium and the traditional Chinese medicine active ingredient are jointly used, levetiracetam is not used alone, the effect of treating cervical spondylosis is obviously achieved, when the levetiracetam is jointly used with the traditional Chinese medicine active ingredient and the diclofenac sodium, the cardiovascular toxicity effect generated by the medicine can be inhibited, meanwhile, the treatment effect of the cervical spondylosis is also improved to a certain extent, and the traditional Chinese medicine and western medicine combined medicine of the application has good treatment effect and safety on the cervical spondylosis.
In yet another embodiment of the present invention,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2-10 parts of pseudo-ginseng, 5-15 parts of ligusticum wallichii, 3-10 parts of corydalis tuber
5-15 parts of white peony root, 8-20 parts of clematis root, 5-15 parts of kudzu vine root
And 8-20 parts of notopterygium root.
Active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 2-4.
In yet another embodiment of the present invention,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2-3 parts of pseudo-ginseng, 7-8 parts of ligusticum wallichii, 5-6 parts of corydalis tuber
7-8 parts of radix paeoniae alba, 10-11 parts of radix clematidis, 7-8 parts of radix puerariae
10-11 parts of notopterygium root.
Active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 3-4.
In yet another embodiment of the present invention,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2.5 parts of pseudo-ginseng, 7.5 parts of szechuan lovage rhizome and 5 parts of corydalis tuber
White peony root 7.5 parts clematis root 10 parts kudzuvine root 7.5 parts
10 parts of notopterygium root;
active ingredients of western medicines: consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 3.
In another embodiment of the present invention, a method for preparing the pharmaceutical composition for treating cervical spondylosis is provided, wherein the method comprises the steps of preparing active ingredients of traditional Chinese medicines, specifically:
(1) pulverizing Notoginseng radix into 100-120 mesh fine powder;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, collecting the distilled water solution in another container, decocting the residue with water for 1 hr, and filtering to obtain filtrate;
(3) decocting radix Puerariae and radix Paeoniae alba with water twice (2 hr for the first time and 1 hr for the second time), mixing the filtrate with the above two water solutions, concentrating, precipitating with ethanol, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(4) reflux-extracting rhizoma Ligustici Chuanxiong and rhizoma corydalis with ethanol, removing residue, recovering ethanol from the extractive solution, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(5) mixing the above two fluid extracts, adding Notoginseng radix powder, mixing, drying, pulverizing into fine powder, adding appropriate amount of rhizoma Peucedani, mixing, and spraying the volatile oil of Notopterygii rhizoma and radix Clematidis.
In another embodiment of the present invention, the present invention provides an application of the pharmaceutical composition for treating cervical spondylosis in preparing a pharmaceutical preparation for treating cervical spondylosis.
In another embodiment of the present invention, a pharmaceutical preparation for treating cervical spondylosis is provided, which is prepared from the pharmaceutical composition and pharmaceutically acceptable excipients.
The medicinal preparation can be prepared into various medicinal dosage forms, such as decoction, pills, capsules, tablets, powder, granules or oral liquid.
Pharmaceutically acceptable excipients in the pharmaceutical formulation include, but are not limited to: diluents include, but are not limited to, sorbitol, mannitol, starch, lactose, powdered or microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, sugars, and the like; filling agent: sodium carboxymethylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, gelatinized starch, and the like; disintegrating agent: dry starch, crospovidone, croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and the like; lubricant: magnesium stearate, sodium lauryl sulfate or aerosil; other adjuvants include one or more of binding agent, flowing agent, composite forming agent, plasticizer, colorant, sweetener, viscosity enhancer, preservative or antioxidant.
The invention is further illustrated by the following examples, which are not to be construed as limiting the invention thereto. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Examples
1. Materials: the cervicodynia granules are prepared from 250 g of pseudo-ginseng, 750 g of ligusticum wallichii, 500 g of corydalis tuber, 1000 g of notopterygium root, 750 g of white paeony root, 1000 g of clematis root and 750 g of kudzuvine root by weight ratio; levetiracetam and diclofenac sodium are commercially available.
2. Animals: wistar rats weighing 180-220 g were provided by the animal testing center of Shandong university.
3. Method and results
The administration formulations for each group of rats are shown in table 1 below. The doses in table 1 are the dose and volume of single administration, and the drugs are prepared into equal volume liquid by normal saline, and are administrated by intragastric administration for 1 time every day and continuously administered for one week. The rats in each group had 6 rats, each half male and female.
TABLE 1
| Group of | Physiological saline | Granules for treating cervicodynia | Diclofenac sodium | Levetiracetam |
| First group | 4ml | 0mg | 0mg | 0mg |
| Second group | 4ml | 800mg | 2mg | 1mg |
| Third group | 4ml | 800mg | 3mg | 1mg |
| Fourth group | 4ml | 800mg | 4mg | 1mg |
| Fifth group | 4ml | 800mg | 0mg | 0mg |
| Sixth group | 4ml | 800mg | 2mg | 0mg |
| Seventh group | 4ml | 800mg | 3mg | 0mg |
| Eighth group | 4ml | 800mg | 4mg | 0mg |
| Ninth group | 4ml | 800mg | 0mg | 1mg |
| Tenth group | 4ml | 0mg | 0mg | 1mg |
| Eleventh group | 4ml | 0mg | 2mg | 0mg |
| Twelfth group | 4ml | 0mg | 3mg | 0mg |
| Group thirteen | 4ml | 0mg | 4mg | 0mg |
The first group is a model group; the second to fourth groups were experimental groups, and the fifth to tenth groups were control groups.
3.1 Effect of each group on ear swelling of rats caused by xylene
After the last administration for 1.5h, the two sides of the right ear of the rat were smeared with xylene (0.1 ml/mouse) to cause inflammation. After 2h of inflammation, the rats are sacrificed, the left and right ear pieces are taken down from the double-ear symmetrical parts by a puncher with the diameter of 10mm, the left and right ear pieces are weighed, and the weight difference of the left and right ear pieces is calculated as the swelling degree. The results are shown in Table 2.
TABLE 2
The results show that the cervicodynia granules and the diclofenac sodium can obviously reduce the ear swelling of the rats.
3.2 Effect on carrageenan-induced toe swelling in rats
After 1.5 hours from the last administration, 0.1ml of 1% carrageenan was subcutaneously injected (SC) into the left hind toe to cause inflammation, the volume of the foot before and after 1 to 4 hours from the initiation of inflammation was measured, and the difference between the volume of the foot before and after the initiation of inflammation was calculated as the degree of swelling, and the results are shown in Table 3.
TABLE 3
Note: compared to the first group, P < 0.05, P < 0.01.
As can be seen from Table 3, the cervicodynia granules and diclofenac sodium have obvious inhibition effect on toe swelling of rats, and the inhibition effect of the second group to the fourth group is obvious and takes effect more quickly.
3.3 analgesic Effect test
After 1.5h of the last administration, the pain threshold of the rats 1-3h after administration (pain threshold of the selected rats (hot plate temperature 55. + -. 0.5 ℃ C.) within 30 seconds) was measured using an autoregulated temperature hotplate apparatus and the results are shown in Table 4.
TABLE 4
Note: compared to the first group, denotes P < 0.05.
The results show that the pain threshold of the rats is improved most obviously and rapidly by the experimental group, and the levetiracetam has no obvious influence on the pain threshold of the rats.
3.4 safety Studies
The administration is continued for 3 weeks according to the administration mode, and the ingestion and water intake, the autonomic activity, the excrement and urine form and the hair color of the rats are observed every day during the administration period; and monitoring physiological signals such as respiration, blood pressure, electrocardio and the like. At 24h after the last dose, each group of rats was sacrificed and subjected to histopathological observation.
The experimental results are as follows:
the rats in the first to fifth groups and the ninth to eleventh groups have no abnormal food intake, autonomic activity, stool and urine morphology, respiration, blood pressure, electrocardiogram and hair color, and no obvious pathological changes are observed in the heart, liver, spleen, lung and kidney after microscopic examination.
In the thirteenth group, one rat experienced arrhythmia on day 18 from the administration, but no significant abnormalities were observed in the heart after microscopic dissection.
Rats in the sixth and seventh groups had arrhythmia from the 15 th day of administration; after the experiment is finished, two rats in the sixth group and the seventh group have arrhythmia; rats in the eighth group have arrhythmia from the 10 th day of administration, after the experiment is finished, three rats reported by the eighth group have arrhythmia, and after microscopic examination, the myocardium of some arrhythmia rats has obvious phenomena of vacuole degeneration, granule degeneration and the like. The results show that certain cardiovascular system toxicity exists when the neck pain granules and the diclofenac sodium are combined, and meanwhile, the levetiracetam can effectively reduce the cardiovascular toxicity effect generated by the combination of the neck pain granules and the diclofenac sodium, and meanwhile, the treatment effect is improved to a certain extent.
It should be noted that the above examples are only used to illustrate the technical solutions of the present invention and not to limit them. Although the present invention has been described in detail with reference to the examples given, those skilled in the art can modify the technical solution of the present invention as needed or equivalent substitutions without departing from the spirit and scope of the technical solution of the present invention.
Claims (10)
1. The pharmaceutical composition for treating cervical spondylosis is characterized in that active ingredients of the pharmaceutical composition comprise the following two parts: (1) the active ingredients of the traditional Chinese medicine are as follows: 1-15 parts of pseudo-ginseng; 3-20 parts of ligusticum wallichii; 2-15 parts of corydalis tuber; 3-20 parts of white peony root; 4-25 parts of clematis root; 3-20 parts of kudzu roots; 4-25 parts of notopterygium root; (2) active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 1-4.
2. The pharmaceutical composition for treating cervical spondylosis as set forth in claim 1,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2-10 parts of pseudo-ginseng, 5-15 parts of ligusticum wallichii, 3-10 parts of corydalis tuber
5-15 parts of white peony root, 8-20 parts of clematis root, 5-15 parts of kudzu vine root
8-20 parts of notopterygium root;
active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 2-4.
3. The pharmaceutical composition for treating cervical spondylosis as set forth in claim 1,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2-3 parts of pseudo-ginseng, 7-8 parts of ligusticum wallichii, 5-6 parts of corydalis tuber
7-8 parts of radix paeoniae alba, 10-11 parts of radix clematidis, 7-8 parts of radix puerariae
10-11 parts of notopterygium root;
active ingredients of western medicines: the composition consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 3-4.
4. The pharmaceutical composition for treating cervical spondylosis as set forth in claim 1,
the traditional Chinese medicine comprises the following components: based on the weight portion, the weight portion of the material,
2.5 parts of pseudo-ginseng, 7.5 parts of szechuan lovage rhizome and 5 parts of corydalis tuber
White peony root 7.5 parts clematis root 10 parts kudzuvine root 7.5 parts
10 parts of notopterygium root;
active ingredients of western medicines: consists of levetiracetam and diclofenac sodium in a weight ratio of 1: 3.
5. The method of preparing a pharmaceutical composition for the treatment of cervical spondylosis as claimed in any one of claims 1 to 4, wherein the method comprises the preparation of active ingredients of the Chinese herbal medicine, specifically:
(1) pulverizing Notoginseng radix into 100-120 mesh fine powder;
(2) extracting volatile oil from Notopterygii rhizoma and radix Clematidis, collecting the distilled water solution in another container, decocting the residue with water for 1 hr, and filtering to obtain filtrate;
(3) decocting radix Puerariae and radix Paeoniae alba with water twice (2 hr for the first time and 1 hr for the second time), mixing the filtrate with the above two water solutions, concentrating, precipitating with ethanol, recovering ethanol, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(4) reflux-extracting rhizoma Ligustici Chuanxiong and rhizoma corydalis with ethanol, removing residue, recovering ethanol from the extractive solution, and concentrating to obtain fluid extract with relative density of 1.25-1.30 at 50 deg.C;
(5) mixing the above two fluid extracts, adding Notoginseng radix powder, mixing, drying, pulverizing into fine powder, adding appropriate amount of rhizoma Peucedani, mixing, and spraying the volatile oil of Notopterygii rhizoma and radix Clematidis.
6. Use of the pharmaceutical composition for the treatment of cervical spondylosis according to any one of claims 1 to 4 for the preparation of a pharmaceutical formulation for the treatment of cervical spondylosis.
7. A pharmaceutical preparation for treating cervical spondylosis, which is characterized by being prepared from the pharmaceutical composition of any one of claims 1 to 4 and pharmaceutically acceptable auxiliary materials.
8. The pharmaceutical preparation according to claim 7, wherein the pharmaceutical preparation is a decoction, a pill, a capsule, a tablet, a powder, a granule or an oral liquid.
9. The pharmaceutical formulation of claim 7, wherein the pharmaceutically acceptable excipient in the pharmaceutical formulation comprises one or more of a diluent, a filler, a disintegrant, a lubricant, a binder, a flow agent, a complex former, a plasticizer, a colorant, a sweetener, a viscosity enhancer, a preservative, or an antioxidant.
10. The pharmaceutical formulation of claim 9, wherein the diluent comprises sorbitol, mannitol, starch, lactose, powdered or microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, or sugar;
the filler comprises sodium carboxymethylcellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose or gelatinized starch;
the disintegrant comprises dry starch, crospovidone, croscarmellose sodium, sodium carboxymethyl starch or low-substituted hydroxypropyl cellulose;
the lubricant comprises magnesium stearate, sodium dodecyl sulfate or superfine silica gel powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010782676.6A CN111888396B (en) | 2020-08-06 | 2020-08-06 | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010782676.6A CN111888396B (en) | 2020-08-06 | 2020-08-06 | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111888396A true CN111888396A (en) | 2020-11-06 |
| CN111888396B CN111888396B (en) | 2022-06-07 |
Family
ID=73247021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010782676.6A Active CN111888396B (en) | 2020-08-06 | 2020-08-06 | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111888396B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113398119A (en) * | 2021-07-30 | 2021-09-17 | 山东明仁福瑞达制药股份有限公司 | Pharmaceutical composition and application of ereoxib in preparation of medicament for resisting cervical spondylotic radiculopathy |
| WO2022160548A1 (en) * | 2021-01-29 | 2022-08-04 | 山东明仁福瑞达制药股份有限公司 | Ointment for treating cervical spondylotic radiculopathy and preparation method therefor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446569A (en) * | 2003-03-24 | 2003-10-08 | 于少华 | Medicament for treating cervical spondylosis and its preparation method |
| WO2009124357A1 (en) * | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
-
2020
- 2020-08-06 CN CN202010782676.6A patent/CN111888396B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446569A (en) * | 2003-03-24 | 2003-10-08 | 于少华 | Medicament for treating cervical spondylosis and its preparation method |
| WO2009124357A1 (en) * | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
Non-Patent Citations (2)
| Title |
|---|
| 王冰；等: "左乙拉西坦的神经保护作用研究进展", 《医学综述》 * |
| 陆小松；等: "双氯芬酸钠的研究进展", 《黑龙江畜牧兽医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022160548A1 (en) * | 2021-01-29 | 2022-08-04 | 山东明仁福瑞达制药股份有限公司 | Ointment for treating cervical spondylotic radiculopathy and preparation method therefor |
| CN113398119A (en) * | 2021-07-30 | 2021-09-17 | 山东明仁福瑞达制药股份有限公司 | Pharmaceutical composition and application of ereoxib in preparation of medicament for resisting cervical spondylotic radiculopathy |
| WO2023004940A1 (en) * | 2021-07-30 | 2023-02-02 | 山东明仁福瑞达制药股份有限公司 | Pharmaceutical composition and application of imrecoxib in preparation of drug for cervical spondylotic radiculopathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111888396B (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| KR102355277B1 (en) | Crude drugs composition for accelerating recovery of bone fracture and bone regeneration | |
| CN111888396B (en) | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof | |
| CN108653581B (en) | Method for preparing medicine for treating hypertension by using white paeony root, dendrobium officinale and irbesartan | |
| CN104689173B (en) | A kind of compound Chinese medicinal preparation for treating gout | |
| CN106421673A (en) | Traditional Chinese medicine composition for treating HPV (human papillomavirus) infection and preparation method thereof | |
| CN113115946A (en) | A method for preparing health food from radix Paeoniae alba and herba Dendrobii | |
| CN104138460A (en) | Chinese medicinal composition for treatment of pains in necks, waists and legs and preparation method thereof | |
| CN105056192A (en) | Traditional Chinese medicine composition for treating myocardial infarction and application thereof | |
| CN106334171B (en) | A kind of Chinese medicine preparation and preparation method for being used to repair hepatic injury | |
| CN102293928A (en) | Chinese medicinal composition for treating hyperuricemia and urarthritis, and preparation method and application thereof | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105343660A (en) | Traditional Chinese medicinal preparation for treating peripheral vertigo and preparation method of traditional Chinese medicinal preparation | |
| CN112587596A (en) | Pharmaceutical composition for treating lymphatic system diseases caused by deficiency fire phlegm stagnation | |
| CN105664053A (en) | Traditional Chinese medicine composition for treating calluses on puncture of internal arteriovenous fistula of maintenance hemodialysis patient | |
| CN105267711A (en) | Pharmaceutical preparation for treating vertigo | |
| CN112057501A (en) | Traditional Chinese medicine composition, traditional Chinese medicine ointment and external hot compress plaster for treating muscular atrophy and myasthenia | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN101112498A (en) | Chinese traditional medicine having functions of promoting blood circulation, relaxing vein and strengthening muscles and bones and method for preparing the same | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN115814020B (en) | Traditional Chinese medicine composition for treating ventricular arrhythmia and application thereof | |
| CN114470114B (en) | Application of Mailuoshutong preparation in preparation of medicine for treating constipation | |
| CN102552724A (en) | Chinese medicine composite for curing hypertension | |
| CN102058681A (en) | Traditional Chinese medicine for treating protrusion of lumbar vertebral disc and waist and leg pain and preparation method thereof | |
| CN105477384A (en) | Traditional Chinese medicine composition capable of reducing blood pressure and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Jie Inventor after: Zhang Yaxin Inventor after: Hao Honghui Inventor after: Chen Kexin Inventor after: Jiang Yujuan Inventor after: Xu Min Inventor after: Gao Chao Inventor after: Pan Ruixue Inventor after: Wang Li Inventor before: Liu Jie Inventor before: Zhang Yaxin Inventor before: Hao Honghui Inventor before: Chen Kexin Inventor before: Jiang Yujuan Inventor before: Xu Min Inventor before: Gao Chao Inventor before: Pan Ruixue Inventor before: Wang Li |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |